anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Axcella Therapeutics · conference-presentation

Axcella Health | Results Presentation Deck | 62 slides

62 pages · 5 arc beats · 2 loops

Conference-Presentation Download JSON
Unlock

Axcella Health | Results Presentation Deck | 62 slides

Axcella Therapeutics · 2022-09
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 5
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 5 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem Statement 1 slides 100% 1/1 slides 100% 1/1 slides · 9 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Complication 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Propose Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides
— 0/1 slides
Key Takeaways 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Evidence 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides

Slide inventory

62
every slide · same image gating as the playbook
01
Slide 1
Includes company logo and ticker symbol.front_matter
Open slide detail
02
front_matter
Open slide detail
03
front_matter
Open slide detail
04
The diagram illustrates a hub-and-spoke model showing systemic interaction of EMMs across various organs.present_solution
Open slide detailBeat · Propose Solution
05
The slide uses a calendar to imply a timeline or duration for Long COVID treatment.establish_context
Open slide detail
06
The slide uses a three-column structure to frame the problem: Market State, Biological Complexity, and Clinical Need.frame_problem
Open slide detailBeat · Problem StatementLoop · Cost Of Inaction
07
The slide uses a timeline framework to show trial progression over time.present_framework
Open slide detailLoop · Cost Of Inaction
08
summarize
Open slide detailBeat · Key TakeawaysLoop · Cost Of Inaction
09
The slide uses a blue box with checkmarks to emphasize the positive attributes of the product.present_solution
Open slide detailLoop · Cost Of Inaction
10
transition
Open slide detailLoop · Cost Of Inaction
11
The slide uses a standard clinical trial flow diagram to illustrate study arms and assessment points.present_framework
Open slide detailLoop · Cost Of Inaction
12
Standard clinical trial subject disposition flow chart.analyze_data
Open slide detailLoop · Cost Of Inaction
13
The table includes demographic, metabolic, inflammatory, and fibrosis markers.analyze_data
Open slide detailLoop · Cost Of Inaction
14
transition
Open slide detailLoop · Cost Of Inaction
15
The data shows a statistically significant improvement in the high-dose group at Week 24.analyze_data
Open slide detailBeat · EvidenceLoop · Cost Of Inaction
16
The slide shows clinical trial data comparing two biomarkers for fibrosis treatment efficacy.analyze_data
Open slide detailLoop · Cost Of Inaction
17
Clinical trial data showing statistically significant reductions in ALT for AXA1125 groups compared to placebo.analyze_data
Open slide detailLoop · Cost Of Inaction
18
Shows statistically significant effects at week 12 for AXA1125 treatment arms.analyze_data
Open slide detailLoop · Cost Of Inaction
19
Data shows proportions of subjects meeting specific thresholds associated with histologic improvements in NASH.analyze_data
Open slide detailLoop · Cost Of Inaction
20
transition
Open slide detailLoop · Cost Of Inaction
21
DMC = Data Monitoring Committee; TEAE = Treatment Emergent Adverse Event; SAE = Serious Adverse Event.summarize
Open slide detailLoop · Cost Of Inaction
22
summarize
Open slide detailLoop · Cost Of Inaction
23
transition
Open slide detailLoop · Cost Of Inaction
24
The slide uses a central biological pathway diagram (liver-centric) surrounded by comparative tables showing single-target drugs vs AXA1125's multi-target appropresent_solution
Open slide detailLoop · Cost Of Inaction
25
The slide uses a central biological pathway map (liver/metabolic focus) flanked by comparison tables showing single-target competitors vs AXA1125's multi-targetdiagnose_problem
Open slide detailLoop · Cost Of Inaction
26
The slide uses bar charts to show dose-dependent increases in metabolic markers and a table to show pathway enrichment scores.analyze_data
Open slide detailLoop · Cost Of Inaction
27
The slide uses a pathway diagram and a bar chart to demonstrate the mechanism of action of AXA1125 in a Primary Human Hepatocyte (PHH) Lipotoxicity Model.analyze_data
Open slide detailLoop · Cost Of Inaction
28
Includes statistical significance markers (*, **, ***) and experimental methodology in the footer.analyze_data
Open slide detailLoop · Cost Of Inaction
29
The slide presents preclinical data from primary human hepatic stellate cells.analyze_data
Open slide detailLoop · Cost Of Inaction
30
summarize
Open slide detailLoop · Cost Of Inaction
31
front_matter
Open slide detailLoop · Cost Of Inaction
32
Includes a map-based visualization of regional prevalence and a grouped bar chart for age/sex demographics.analyze_data
Open slide detailLoop · Cost Of Inaction
33
Uses a before-after-bridge framework to highlight the growth in Fibrosis stage 2-4 prevalence.analyze_data
Open slide detailLoop · Cost Of Inaction
34
Data source: Harrison SA et al. J Hepatol. 2021;S0168-8278:00176-8.analyze_data
Open slide detailLoop · Cost Of Inaction
35
The slide uses a background diagram of biological pathways to illustrate complexity, overlaid with a callout box containing the core thesis.frame_problem
Open slide detailBeat · ComplicationLoop · Cost Of Inaction
36
Uses a gradient bar to illustrate the shift in risk tolerance and clinical priorities.frame_situation
Open slide detailLoop · Cost Of Inaction
37
The slide uses a table structure to categorize drug candidates by their biological mechanism of action.present_solution
Open slide detail
38
The slide outlines a clinical trial protocol for AXA1125.present_framework
Open slide detail
39
The slide includes a prominent callout box summarizing the clinical significance of the baseline data.analyze_data
Open slide detail
40
transition
Open slide detail
41
The slide uses a simple three-circle layout to categorize the utility of NITs.present_framework
Open slide detail
42
The slide uses a simple Venn-like or hub-and-spoke visual, though the side circles are empty.establish_context
Open slide detail
43
The slide compares three groups (Placebo, AXA1125 22.6 BID, AXA1125 33.9 BID) across two time points (Week 12 and Week 24).analyze_data
Open slide detail
44
The chart compares different trial durations (24 weeks vs 72 weeks vs 18 months) and phases (Ph2b vs Ph3).compare_peers
Open slide detail
45
The slide title mentions week 12, but the charts explicitly label week 24. This is a common discrepancy in clinical trial decks where data is presented across manalyze_data
Open slide detail
46
N=931. Data presented for Placebo, OCA 10mg, and OCA 25mg cohorts.analyze_data
Open slide detail
47
The slide presents longitudinal data from the REGENERATE trial, specifically focusing on FIB-4 scores as a non-invasive test (NIT) for fibrosis.analyze_data
Open slide detail
48
P-values are calculated using Cochran-Mantel Haenszel test vs placebo.analyze_data
Open slide detail
49
Figure 5 from a clinical study publication; includes legend for treatment arms.illustrate_case
Open slide detail
50
The slide uses a forest plot to visualize odds ratios and confidence intervals for clinical predictors.analyze_data
Open slide detail
51
The slide uses a dark sidebar for context and a white main area for data presentation. It includes a citation at the bottom.analyze_data
Open slide detail
52
The slide highlights the efficacy of MGL-3196 in NASH treatment using MRI-PDFF as a biomarker.analyze_data
Open slide detail
53
Figure 3 from Stine JG, Munaganuru. Clin Gastroenterol Hepatol. 2021 Nov.analyze_data
Open slide detail
54
transition
Open slide detail
55
The table compares Placebo, AXA1125 22.6 BID, and AXA1125 33.9 BID groups.analyze_data
Open slide detail
56
summarize
Open slide detail
57
Standard corporate closing slide with branding and page number.summarize
Open slide detail
58
The chart compares different trial durations (24 weeks vs 72 weeks vs 18 months) and phases (Ph2b vs Ph3).compare_peers
Open slide detail
59
Includes a biological pathway diagram and patient population statistics.summarize
Open slide detail
60
The slide uses checkmarks to indicate completed milestones.summarize
Open slide detail
61
state_next_steps
Open slide detail
62
summarize
Open slide detail